{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T14:33:15Z","timestamp":1777905195698,"version":"3.51.4"},"reference-count":41,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI14C1063"],"award-info":[{"award-number":["HI14C1063"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI15C1537"],"award-info":[{"award-number":["HI15C1537"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2017,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p><jats:italic>para<\/jats:italic>-Aminosalicylic acid (PAS) is a second-line antituberculosis drug that has been used to treat multidrug-resistant and extensively drug-resistant tuberculosis for more than 60 years. Renal secretion and glomerular filtration are the major pathways for the elimination of PAS. We comprehensively studied PAS transport by using cell lines that overexpressed various transporters and found that PAS acts as a novel substrate of an organic anionic polypeptide (OATP1B1), organic cationic transporters (OCT1 and OCT2), and organic anion transporters (OAT1 and OAT3) but is not a substrate of any ATP-binding cassette (ABC) transporters. Net PAS uptake was measured, and the transport affinities (<jats:italic>K<jats:sub>m<\/jats:sub><\/jats:italic>values) for OATP1B1, OCT1, OCT2, OAT1, and OAT3 were found to be 50.0, 20.3, 28.7, 78.1, and 100.1 \u03bcM, respectively. The net uptake rates suggested that renal OAT1 and OAT3 play relatively major roles in PAS elimination. The representative inhibitors rifampin for OATP1B1, probenecid for OAT1 and OAT3, and verapamil for OCT1 and OCT2 greatly inhibited PAS uptake, suggesting that PAS is dependent on multiple transporters for uptake. We also evaluated nonsteroidal anti-inflammatory drugs (NSAIDs), proton pump inhibitors (PPIs), and metformin for the inhibition of PAS uptake via these transporters. Half-maximal (50%) inhibitory concentrations (IC<jats:sub>50<\/jats:sub>s) were kinetically determined and used to predict the drug-drug interactions (DDIs) affecting these transporters' activity toward PAS. We found that rifampin, probenecid, ibuprofen, naproxen, cimetidine, and quinidine each exhibited a significant potential for<jats:italic>in vivo<\/jats:italic>DDIs with PAS. In this study, PAS was found to be a novel substrate of several transporters, and drugs that inhibit these transporters can reduce PAS elimination.<\/jats:p>","DOI":"10.1128\/aac.02392-16","type":"journal-article","created":{"date-parts":[[2017,2,22]],"date-time":"2017-02-22T01:30:22Z","timestamp":1487727022000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":21,"title":["Evaluation of<i>para<\/i>-Aminosalicylic Acid as a Substrate of Multiple Solute Carrier Uptake Transporters and Possible Drug Interactions with Nonsteroidal Anti-inflammatory Drugs<i>In Vitro<\/i>"],"prefix":"10.1128","volume":"61","author":[{"given":"M. Masud","family":"Parvez","sequence":"first","affiliation":[{"name":"Department of Pharmacology and PharmacoGenomics Research Center, Inje University College of Medicine, Busan, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho Jung","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and PharmacoGenomics Research Center, Inje University College of Medicine, Busan, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Ah","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Inje University Busan Paik Hospital, Busan, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Gook","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and PharmacoGenomics Research Center, Inje University College of Medicine, Busan, Republic of Korea"},{"name":"Department of Clinical Pharmacology, Inje University Busan Paik Hospital, Busan, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","first-page":"953","article-title":"Twenty years afterward historical notes on the discovery of the antituberculosis effect of paraaminosalicylic acid (PAS) and the first clinical trials","volume":"90","author":"Lehmann J","year":"1964","unstructured":"Lehmann J . 1964. Twenty years afterward historical notes on the discovery of the antituberculosis effect of paraaminosalicylic acid (PAS) and the first clinical trials. Am Rev Respir Dis90:953\u2013956.","journal-title":"Am Rev Respir Dis"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.2004.04120.x"},{"key":"e_1_3_3_4_2","volume-title":"para-Aminosalicylic acid Lucane","author":"European Medicines Agency","year":"2013","unstructured":"European Medicines Agency. 2013. para-Aminosalicylic acid Lucane. European Medicines Agency, London, United Kingdom."},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262150-00001"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600630512"},{"key":"e_1_3_3_7_2","first-page":"169","article-title":"The role of the metabolism of p-aminosalicylic acid (PAS) in the treatment of tuberculosis. Interaction with the metabolism of isonicotinic acid hydrazide (INH) and the synthesis of cholesterol","volume":"50","author":"Lehmann J","year":"1969","unstructured":"Lehmann J . 1969. The role of the metabolism of p-aminosalicylic acid (PAS) in the treatment of tuberculosis. Interaction with the metabolism of isonicotinic acid hydrazide (INH) and the synthesis of cholesterol. Scand J Respir Dis50:169\u2013185.","journal-title":"Scand J Respir Dis"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.475798"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(54)92552-0"},{"key":"e_1_3_3_10_2","first-page":"1","article-title":"Progress report on therapeutic and toxic effects of combinations of isoniazid, streptomycin, and para-aminosalicylic acid; United States Public Health Service cooperative investigation of antimicrobial therapy of tuberculosis","volume":"69","author":"Egelund EF","year":"1954","unstructured":"Egelund EF . 1954. Progress report on therapeutic and toxic effects of combinations of isoniazid, streptomycin, and para-aminosalicylic acid; United States Public Health Service cooperative investigation of antimicrobial therapy of tuberculosis. Am Rev Tuberc69:1\u201312.","journal-title":"Am Rev Tuberc"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/1752-153X-7-72"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02513.x"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.32.6.647"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/0471140856.tx0425s33"},{"key":"e_1_3_3_15_2","volume-title":"MDR-TB guidelines","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. 2015. MDR-TB guidelines. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.05.011"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2008.10.016"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3028"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.235"},{"key":"e_1_3_3_20_2","first-page":"228","article-title":"The effect of probenecid (benemid) in enhancing para-aminosalicylic acid concentrations in the blood","volume":"66","author":"Breitenbucher RB","year":"1952","unstructured":"Breitenbucher RB AmatuzioDS FalkA. 1952. The effect of probenecid (benemid) in enhancing para-aminosalicylic acid concentrations in the blood. Am Rev Tuberc66:228\u2013232.","journal-title":"Am Rev Tuberc"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI102651"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1590\/S1806-37132010000500017"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.2165\/11317030-000000000-00000"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2014.103"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A088"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1099\/00221287-12-1-76"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078313"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.114.058529"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03303.x"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01151-16"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2006.12.006"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.106.013581"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.61"},{"key":"e_1_3_3_34_2","volume-title":"Drug interaction studies\u2014study design, data analysis, implications for dosing, and labeling recommendations","author":"Food and Drug Administration","year":"2012","unstructured":"Food and Drug Administration. 2012. Drug interaction studies\u2014study design, data analysis, implications for dosing, and labeling recommendations. Food and Drug Administration, Silver Spring, MD."},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.170159"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02765-15"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.19.13675"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.104.068056"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.114.059105"},{"key":"e_1_3_3_40_2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0031-6997(24)01372-3","article-title":"Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver","volume":"50","author":"Ito K","year":"1998","unstructured":"Ito K IwatsuboT KanamitsuS UedaK SuzukiH SugiyamaY. 1998. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev50:387\u2013412.","journal-title":"Pharmacol Rev"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100038"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01255-13"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02392-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02392-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T15:26:32Z","timestamp":1750001192000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02392-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.1128\/AAC.02392-16"],"URL":"https:\/\/doi.org\/10.1128\/aac.02392-16","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"2016-11-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-02-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-04-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02392-16"}}